Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Pentheroudakis

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 22, 2008
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group StudyH P Kalofonos, A Bamias, A Koutras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2020
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusionsT Yoshino, G Pentheroudakis, S Mishima, et al.
ESMO Open|April 16, 2024
ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancerP M Carrera, G Curigliano, D Santini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupJ Pascual, G Attard, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)E Y T Wong, L Verlingue, M Aldea, et al.
ESMO Open|April 22, 2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoringB Gyawali, E G E de Vries, U Dafni, et al.
ESMO Open|June 7, 2023
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databasesP Martin, Z Tsourti, J Ribeiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2024
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug developmentC B Westphalen, D Martins-Branco, J R Beal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2020
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOSY H Park, E Senkus-Konefka, S-A Im, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|July 22, 2008
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group StudyH P Kalofonos, A Bamias, A Koutras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2020
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusionsT Yoshino, G Pentheroudakis, S Mishima, et al.
ESMO Open|April 16, 2024
ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancerP M Carrera, G Curigliano, D Santini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupJ Pascual, G Attard, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)E Y T Wong, L Verlingue, M Aldea, et al.
ESMO Open|April 22, 2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoringB Gyawali, E G E de Vries, U Dafni, et al.
ESMO Open|June 7, 2023
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databasesP Martin, Z Tsourti, J Ribeiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2024
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug developmentC B Westphalen, D Martins-Branco, J R Beal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2020
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOSY H Park, E Senkus-Konefka, S-A Im, et al.
Pageof 10